Dupilumab shows clinical benefit in localised scleroderma trial

A randomised, placebo-controlled phase 2 study (NCT04200755) evaluated six months of IL-4-receptor-alpha blockade with dupilumab in localised scleroderma. The trial reported significant clinical improvement over placebo, attenuation of local inflammation, reduction of the IL-4/IL-13-dependent gene signature, and partial suppression of fibrosis-related gene expression. The authors state the findings suggest a role for IL-4/IL-13 signalling in this fibrosing disease and raise the possibility of relevance to other fibrosing conditions.

Most relevant for: Patients with localised scleroderma being considered for clinical trials or novel fibrosis-targeted therapies.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.